Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7603249 | 0.84 | ALDH1A1 (0.55) | ALDH1A1HSD17B10KDM4EHPGDTDP1 | |
| SCHEMBL12084074 | 0.80 | CCR1 (0.46) | ALDH1A1HSD17B10KDM4EHPGDCCR1 | |
| SCHEMBL6449500 | 0.78 | SLC40A1 (0.47) | ALDH1A1HSD17B10KDM4EHPGDCCR1 | |
| SCHEMBL2565378 | 0.78 | CCR1 (0.44) | ALDH1A1HSD17B10KDM4EHPGDCCR1 | |
| SCHEMBL9487069 | 0.77 | CCR1 (0.48) | ALDH1A1HSD17B10KDM4EHPGDCCR1 | |
| SCHEMBL12780478 | 0.77 | CCR1 (0.43) | ALDH1A1HSD17B10KDM4EHPGDCCR1 | |
| Hydrochloric Acid SCHEMBL28105366 | 0.77 | CCR1 (0.43) | ALDH1A1HSD17B10KDM4EHPGDCCR1 | |
| SCHEMBL989588 | 0.76 | CYP3A4 (0.50) | ALDH1A1HSD17B10HPGDTDP1SLC40A1 | |
| SCHEMBL8212123 | 0.75 | SLC40A1 (0.53) | ALDH1A1HSD17B10KDM4EHPGDCCR1 | |
| SCHEMBL14815626 | 0.75 | ALDH1A1 (0.46) | ALDH1A1HSD17B10KDM4EHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| CN-113226356-B | Activation of pyruvate kinase R | 诺沃挪第克健康护理股份公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4148050-B1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2024-12-18 | — | — | EP | disclosed |
| US-12122778-B2 | Activating pyruvate kinase R | NOVO NORDISK HEALTH CARE AG (CH) | 2024-10-22 | — | — | US | disclosed |
| EP-4436955-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-3852791-B1 | ACTIVATING PYRUVATE KINASE R | NOVO NORDISK HEALTHCARE AG (CH) | 2024-07-03 | — | — | EP | disclosed |
| CN-115884968-B | Novel acid secretion inhibitor and use thereof | 日东制药株式会社 | 2024-06-21 | — | — | CN | disclosed |
| CN-117858879-A | CDK2/4/6 inhibitor and preparation method and application thereof | 南京再明医药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | disclosed |
| CN-1444481-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | disclosed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | disclosed |
| EP-1307204-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| CN-1350458-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-05-22 | — | — | CN | disclosed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | ALDH1A1 3651/4885HSD17B10 3057/4885KDM4E 917/4885 |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | ALDH1A1 3306/4885HSD17B10 3981/4885KDM4E 2441/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | ALDH1A1 3651/4885HSD17B10 3057/4885KDM4E 917/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | ALDH1A1 3651/4885HSD17B10 3057/4885KDM4E 917/4885 |
| US-12122778-B2 | Activating pyruvate kinase R | PDK1, PDK2, PKLR | ALDH1A1 3597/4885HSD17B10 1924/4885KDM4E 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.